RXST Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -14.77% compared to RxSight's net margin of --. RxSight's return on equity of -11.86% beat Perspective Therapeutics's return on equity of --.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 67.74%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 677.99%. Given that Perspective Therapeutics has higher upside potential than RxSight, analysts believe Perspective Therapeutics is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are larger than Perspective Therapeutics quarterly revenues of --. RxSight's net income of -$5.9M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, RxSight's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.03x versus 11.98x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystems Holdings has a net margin of -14.77% compared to RxSight's net margin of 2.76%. RxSight's return on equity of -11.86% beat InfuSystems Holdings's return on equity of 4.33%.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 67.74%. On the other hand InfuSystems Holdings has an analysts' consensus of $14.13 which suggests that it could grow by 183.64%. Given that InfuSystems Holdings has higher upside potential than RxSight, analysts believe InfuSystems Holdings is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.898, suggesting its more volatile than the S&P 500 by 89.81%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are larger than InfuSystems Holdings quarterly revenues of $33.8M. RxSight's net income of -$5.9M is lower than InfuSystems Holdings's net income of $933K. Notably, RxSight's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 49.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.03x versus 0.80x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of -14.77% compared to RxSight's net margin of -27.63%. RxSight's return on equity of -11.86% beat PROCEPT BioRobotics's return on equity of -31.74%.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 67.74%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $90.88 which suggests that it could grow by 72.08%. Given that PROCEPT BioRobotics has higher upside potential than RxSight, analysts believe PROCEPT BioRobotics is more attractive than RxSight.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are smaller than PROCEPT BioRobotics quarterly revenues of $68.2M. RxSight's net income of -$5.9M is higher than PROCEPT BioRobotics's net income of -$18.9M. Notably, RxSight's price-to-earnings ratio is -- while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.03x versus 12.26x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -14.77% compared to RxSight's net margin of -18.58%. RxSight's return on equity of -11.86% beat Retractable Technologies's return on equity of -16.83%.

RxSight has a consensus price target of $24.36, signalling upside risk potential of 67.74%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that RxSight has higher upside potential than Retractable Technologies, analysts believe RxSight is more attractive than Retractable Technologies.

RxSight has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

RxSight has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. RxSight pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

RxSight quarterly revenues are $40.2M, which are larger than Retractable Technologies quarterly revenues of $10.3M. RxSight's net income of -$5.9M is lower than Retractable Technologies's net income of -$1.9M. Notably, RxSight's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for RxSight is 4.03x versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.